Researchers find key to cancer dormancy 


Helium Summary: Studies show that the enzyme G9a plays a crucial role in allowing breast cancer cells to become dormant and evade hormone therapy, leading to potential relapses years after initial treatment.

Inhibition of G9a could prevent this dormancy and improve relapse prevention [Weekly Standard].

March 29, 2024


Researchers from The Institute of Cancer Research in London discovered how breast cancer cells avoid treatment by entering dormancy [Weekly Standard].

Inhibition of the enzyme G9a prevented dormancy in cancer cells and killed cells already hibernating [Weekly Standard].


Medical Researcher

This discovery could be groundbreaking for the future of cancer treatment, as it offers a targeted approach towards preventing cancer recurrence [Weekly Standard].

Cancer Survivor

These findings provide hope for better long-term outcomes but also raise concerns about current treatment efficacy [Weekly Standard].


While the results are promising, there’s an impending need for clinical trials to translate this knowledge into practice [Weekly Standard].


How does G9a affect cancer dormancy?

G9a enables breast cancer cells to enter a dormant state, allowing them to survive hormone therapy and potentially cause a relapse [Weekly Standard].

What is the significance of targeting dormant cancer cells in treatment?

Targeting dormant cancer cells can prevent future cancer relapses, thereby improving long-term patient outcomes [Weekly Standard].

News Media Bias (?)

The sources seem to objectively present findings from recent research without ideological slant.

However, the complexity of cancer treatments and the variable success rates across different studies suggest a need for careful interpretation of any single study's results.


The story focuses on a specific aspect of cancer treatment - the avoidance of cell dormancy, which is critical for preventing relapses.


Understanding cancer dormancy mechanisms unlocks potential strategies for improved treatments, offering a beacon of hope for prolonged remission and possibly even a cure [Weekly Standard].

Potential Outcomes

Clinical trials confirm G9a inhibition efficacy, leading to new standard treatment, with a high probability given research backing .

Further study reveals side effects or less effectiveness in diverse populations, highlighting the complexity of cancer biology .


Popular Stories

Sort By:                     

Increase your understanding with more perspectives. No ads. No censorship.


Chat with Helium

 Ask me any question!